Vincristine-induced unilateral ptosis with serendipitous response to modafinil.
Here we describe a scenario of an atypical manifestation of vincristine-induced neurotoxicity, which responded serendipitously to modafinil. Atypical in that this patient had developed a uniocular ptosis, a rare manifestation of vincristine-induced neurotoxicity. The improvement in neurotoxicity after modafinil was started to alleviate morphine-induced sedation was quite noteworthy.
Department of Radiation Therapy and Oncology, Regional Cancer Center, Shimla, India. swarooptheone@gmail.com
Swaroop
S
Revannasiddaiah
Tapesh
T
Bhattacharyya
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D001763:Blepharoptosis / Q000139:chemically induced* / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D000077408:Modafinil; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D001559:Benzhydryl Compounds; D018696:Neuroprotective Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000077408:Modafinil; D011241:Prednisone